Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 69 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnNCT03773744Phase 1
• A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)CompletedNCT03773666Phase 1
• Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• MRD-guided Treatment in NPM1mut AML PatientsTerminatedNCT03769532Phase 2
• VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingNCT03769155Phase 1
• Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder CancerActive, not recruitingNCT03768570Phase 2
• Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract CancerWithdrawnNCT03768531Phase 2
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeWithdrawnNCT03767439Phase 2
• Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03766178Phase 2
• Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeStatus unknownNCT03765775Phase 2
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsCompletedNCT03762447Phase 1
• MGD019 DART® Protein in Unresectable/Metastatic CancerCompletedNCT03761017Phase 1
• Efficacy of Durvalumab in Non-muscle-invasive Bladder CancerStatus unknownNCT03759496Phase 2
• IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedNCT03758781Phase 1
• Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.WithdrawnNCT03758729Phase 2
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownNCT03757936Phase 1
• Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C MelanomaActive, not recruitingNCT03757689Phase 2
• PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.CompletedNCT03755440Phase 2
• SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung CancerStatus unknownNCT03755115Phase 2
• Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate CancerStatus unknownNCT03753243Phase 2
• Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)CompletedNCT03752723Phase 1/2
• A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1
• GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel StudyCompletedNCT03751761Phase 1/2
• Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03749018Phase 2
• Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )CompletedNCT03748134Phase 3
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCCWithdrawnNCT03746249Phase 2
• Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric CancerCompletedNCT03745170Phase 3
• Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerActive, not recruitingNCT03744793Phase 2
• A Study of CS1001 in Subjects with Advanced Solid TumorsCompletedNCT03744403Phase 1
• Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCCWithdrawnNCT03744247Phase 3
• Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated GlioblastomaActive, not recruitingNCT03743662Phase 2
• Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.Status unknownNCT03737968Phase 2
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
• KN046 in Subjects With Advanced Solid Tumors and LymphomaCompletedNCT03733951Phase 1
• Pembrolizumab in Treating Participants With Recurrent Ovarian CancerActive, not recruitingNCT03732950Phase 2
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
• SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell CancerStatus unknownNCT03732508Phase 2
• CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer PatientsStatus unknownNCT03732430Phase 2
• Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA)CompletedNCT03732391Phase 2
• GR1405 Injection in Patients With Advanced Solid Tumor or LymphomaStatus unknownNCT03731390Phase 1
• Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1
• A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung CancerCompletedNCT03728556Phase 3
• Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
• Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHNCompletedNCT03726775Phase 2
• CART-EGFRvIII + Pembrolizumab in GBMCompletedNCT03726515Phase 1
• Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell TumorsWithdrawnNCT03726281Phase 2
• Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Active, not recruitingNCT03725059Phase 3
• FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/PaclitaxelCompletedNCT03723967Phase 2
• SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After SurgeryStatus unknownNCT03722875Not applicable
• A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin LymphomaCompletedNCT03722147Phase 1/2
• CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity CancerCompletedNCT03721757Phase 2
• FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer PatientsCompletedNCT03721653Phase 2
• Avelumab With Radiotherapy in Patients With Leptomeningeal DiseaseCompletedNCT03719768Phase 1
• SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer PatientsTerminatedNCT03716596Phase 1
• A Safety Study of LY3462817 in Healthy ParticipantsCompletedNCT03715192Phase 1
• Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid TumorsCompletedNCT03713905Phase 1
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1
• Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP TrialActive, not recruitingNCT03712605Phase 3
• Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)Status unknownNCT03711305Phase 3
• Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT03708224Phase 2
• Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT03707509Phase 3
• PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid TumorsWithdrawnNCT03706274Phase 1
• Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
• Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.Active, not recruitingNCT03704480Phase 2
• Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid TumorsStatus unknownNCT03704246Phase 2
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2
• Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)Active, not recruitingNCT03703050Phase 2
• PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2
• Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Phase 3
• Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
• Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical CystectomyActive, not recruitingNCT03697850Phase 2
• Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaTerminatedNCT03696212Phase 1/2
• Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)CompletedNCT03695510Phase 2
• Window of Opportunity Pilot Study of Pembrolizumab in Obesity-driven Endometrial CancerTerminatedNCT03694834Early Phase 1
• A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell CarcinomaWithdrawnNCT03693573Phase 3
• PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic AbnormalitiesStatus unknownNCT03693326Phase 2
• Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric AdenocarcinomaActive, not recruitingNCT03691454Phase 2/3
• Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal CancerCompletedNCT03691090Phase 3
• VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1
• PEnile Cancer Radio- and Immunotherapy CLinical Exploration StudyCompletedNCT03686332Phase 2
• Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid TumorsTerminatedNCT03684785Phase 1/2
• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3
• TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver CancerActive, not recruitingNCT03680508Phase 2
• A Study to Investigate the Safety of AB680 in Healthy VolunteersCompletedNCT03677973Phase 1
• A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade OsteosarcomaStatus unknownNCT03676985Phase 1/2
• A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical CancerStatus unknownNCT03676959Phase 1
• A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial CarcinomaStatus unknownNCT03676946Phase 1/2
• Safety of ADU-1604 in Adults With Metastatic MelanomaTerminatedNCT03674502Phase 1
• Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)CompletedNCT03674424Phase 2
• A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingNCT03673787Phase 1/2
• Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCCWithdrawnNCT03673735Phase 3
• Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCCStatus unknownNCT03671265Not applicable
• A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Phase 3
• Dabrafenib + Trametinib + PDR001 In Colorectal CancerStatus unknownNCT03668431Phase 2
• COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.CompletedNCT03667716Phase 1
• KN035 for dMMR/MSI-H Advanced Solid TumorsActive, not recruitingNCT03667170Phase 2
• A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLCTerminatedNCT03666728Phase 2

← Immune Checkpoint Inhibitors overview